Join collection
Hello, welcome to our official website!
互联网保险需要三思而后行
2019-01-12

  2018年可能成为我国互联网保险发展的一个“关口”,或是一个“转折”,因此,“今非昔比”既是状态,更应是心态,在这个历史背景下,互联网保险*需要的是“三思而后行”,不仅是回顾历史的反思与总结,更是面向未来的清晰与坚定。


  我国互联网保险经过了十几年的发展,取得的成绩可谓是有目共睹,但与此同时也面临着许多突出问题和深层次矛盾,尤其是2016年以来,互联网保险的发展出现了较大的“跌宕起伏”。于是,有人困惑,也有人疑惑,更有人批评,甚至是指责。但殊不知,任何一个新生事物的成长都会面临“跌宕起伏”,甚至是“磕磕碰碰”,这既是成长的代价,更是发展的必然。

  2018年可能成为我国互联网保险发展的一个“关口”,或是一个“转折”,因此,“今非昔比”既是状态,更应是心态。在这个历史背景下,互联网保险*需要的是“三思而后行”,不仅是回顾历史的反思与总结,更是面向未来的清晰与坚定。

  回顾历史,我国互联网保险在推动保险业改革、创新与发展过程中发挥了重要和独特的作用,可以用三句话概括,一是异军突起,作用显著。作为一种新生力量,互联网保险不仅是提高了效率,更创造了可能,解决了许多发展、改革和服务中的“瓶颈”和“*后一公里”问题,推动了行业的创新与进步,可谓是作用显著,功不可没。二是各美其美,相得益彰。在互联网保险的发展过程中,不仅有传统的保险企业,也有互联网保险企业。不仅有保险企业,也有互联网保险科技企业,还有互联网科创企业。他们相互协同,交相辉映,取长补短,共同创新。三是科技赋能,重塑保险。互联网保险*大贡献在于科技赋能,通过对时空的再认识与利用,变不可能为现实,不仅是结构性降低了运营成本,更解决了经营过程中的风险、信用和效率等难题,实现了商业模式的迭代,同时,实现了碎片化和场景化的创新。

  这是一个快速变化的时代,快的让人有点“猝不及防”,就来不及“思”,更没有时间“想”。没有了思想,缺乏了理论,淡漠了文化,就难免冲动、盲目、浮躁,乃至“任性”。都说“这个世界**不变的就是变化”,于是,人们就忙于“变化”,殚精竭虑,身心俱疲,蓦然回首,却迷茫于“我是谁”。但在中国古人看来,世界是变的,世界更是不变的。人,只有把握好不变的,才能够把握未来。中国人称这种“不变”为“常”,为“道”。 有的时候,人们觉得“道”是一个玄乎其玄的东西,一个远在天边的东西。殊不知,当你觉悟了,“道”就在你的眼前身边。把握好“道”是为人处世的根本和基础,因为,古人说:得道者,得天下。

  互联网保险面临自我迭代的挑战,这种挑战,不单是技术,也不仅是商业,而是思想、理论、理念与文化。因为,离开理论的实践,注定是盲目的实践。因为,一支没有文化的军队,注定是要打败战的。互联网保险是要探索一条“前无古人”的路,没有“前车之鉴”,靠什么指引方向,靠理论,靠文化。要做到这一点,就需要不断地反思,正如孔子在听说季文子每每做事均“三思而后行”时说:再,斯可矣,讲的是借鉴以往的重要。无论是“思”,还是“再”,其本质均是“省”,因此,古人说:吾日三省吾身。在互联网保险的发展过程中,尤其需要不断地回顾、反思和检讨,需要不断的“三思”和“三省”,继而问道于心,明心见性,且行且珍惜。

  “三思”的第一“思”是回答“为什么”,即为什么做互联网保险。

  “为什么”的背后是“为了谁”,即发展互联网保险的宗旨问题。这个问题看似简单,但却经不起“推敲”。今天,从事互联网保险的人可谓是来自“五湖四海”,但并非都是为了一个“共同的目标”走到一起。相信大多数人肯定是为了理想而来,但也不乏个别“心怀叵测”的投机者,想的是“赶时髦”、“炒概念”,然后“套现走人”。人们为什么而来,即为什么做互联网保险,或者是为了谁做互联网保险,似乎已成为了所有问题的“结”。提出这个问题,是因为有些人也许太忙了,并没有认真“思”过这个问题,稀里糊涂地就来做互联网保险,就难免做的稀里糊涂。当然,或许有些人也想过,却“难以启齿”,或“不可告人”。

  中国古人推崇:修身齐家治国平天下。纵观互联网保险的发展过程,特别是出现的乱象和存在的问题,症结就出在“修身”。而“修身”的关键是回答:为什么。这既是问题所在,也是成功的关键。“为什么”的问题回答好了,就不容易出问题,就能够成功。所以,每一个做互联网保险的人,首先要解决好“修身”与“齐家(公司)”的问题,即“为什么”和“为了谁”的问题,因为,这是你的出发,你的初心,是你“行走于江湖”的依靠与寄托。如果根本和基础问题解决不好,那么,离成功就可能“相去甚远”,更别谈什么“治国”与“平天下”。

  作为一种互联网平台,流量肯定是“意义非凡”,因为,得流量者,得天下。作为一家公司,故事很重要,投资者买的就是“故事”。作为一个创业团队,资本更是重要,没有了资本青睐,再好的理想抱负,也只能是想想而已。虽然流量、故事和资本都重要,而且很重要,但它们肯定不是互联网保险的根本和全部。互联网保险*重要的是发挥自身的特点和优势,提**率,创造可能,而更重要的是为客户创造价值,福祉行业和社会。

  这些年,互联网保险,特别是互联网车险,“井喷式”发展是它,“塌陷式”下滑也是它,让外人看的是“一头雾水”,局中人则“心知肚明”。从表面上看,都是“15%”惹的祸,但从根本上讲,仍是跳不出“掩耳盗铃”和“自欺欺人”的局限,忘记了心存敬畏是做人做事的根本道理。

  明白大道理并不难,难的是知行合一,难的是先后顺序。传统文化中有“己欲立而立人,己欲达而达人”的智慧,讲的是先人后己,成人达己。无论是保险,还是互联网保险,都面临这个问题,即是先成人,还是先达己。许多时候,人们更多地是想“达己”,结果往往是事与愿违,欲速不达。佛家讲:渡人渡己。把别人渡到了彼岸,蓦然回首,你已然在彼岸。互联网保险的发展*需要的就是这种智慧,而*缺的也是这种智慧。

  “三思”的第二“思”是回答“是什么”,即互联网保险到底是什么。

  古人说:凡事预则立,不预则废。这句话的后面还有一段:言前定则不跲,事前定则不困,行前定则不疚,道前定则不穷。讲的是说话办事,尤其是办大事之前,务必先把一些根本性的问题想清楚,弄明白。就互联网保险而言,也面临这个问题,互联网保险到底是什么,是渠道,是营销手段,还是商业模式。这些问题如果还没有想清楚,弄明白,在做的过程中就可能面临困惑、纠结,乃至迷茫。

  随着互联网保险公司的出现,作为一种商业模式,似乎已是不言而喻了。但互联网保险公司的出现并不等于互联网保险商业模式的成熟,它只是为探索互联网保险商业模式提供了一种“机缘”,因此,什么是互联网保险,什么是互联网保险的基础理论、基本原理,互联网保险发展的基本逻辑是什么,互联网保险的核心能力是什么,它的商业模式是什么,诸如此类,林林总总的问题仍有待人们回答,特别是通过实践去回答。古人说:君子务本,本立道生。互联网保险也一样,上述问题均属于互联网保险的根本性问题,如果这些问题回答不好,就可能找不到自己的“初心”,就容易“本末倒置”,“忘乎所以”,甚至是“舍本逐末”,“误把他乡做故乡”,就不可能做好互联网保险。

  “三思”的第三“思”是回答“做什么”,即互联网保险做什么。

  互联网保险,属于“前无古人”的事业,因此,需要“摸着石头过河”,在战争中学习战争,在不断的探索与实践中回答互联网保险是什么的问题。当下有一个观点经常被滥用,就是“试错”。积极实践,大胆探索固然重要,但所有的实践与探索均应当是理性的,应当在理论的指导下开展的,否则就是盲目,甚至是愚昧。就互联网保险而言,可以肯定的是:并不是所有的保险产品均适合互联网经营模式的。互联网保险也面临“有所为有所不为”的问题。更重要的是:互联网保险有其独特的优势,但这些优势也需要“善加利用”。现在有些互联网保险业务是建立在保险业发展过程中存在的“问题”基础上,比如“借个道”、“开张票”和“垫点钱”,尽管也能够实现“商业模式”,甚至赚得“盆满钵满”,但肯定不是互联网保险发展的“正道”,还可能“误了卿卿性命”。因此,互联网保险的发展,需要回答的往往不是能够做什么,而是应该做什么。

  互联网发展到了今天,尤其是在商业领域的应用,发挥的作用,取得的成绩是有目共睹的,并形成了独特的“商业模式”,但其中的许多做法,仍有待时间检验。但就互联网保险而言,则“又当别论”,作为一种金融制度安排,保险具有很强的特殊性,因此,不能简单地“拥抱”互联网,可以肯定:不是所有互联网的“成功经验”均适合互联网保险经营,这就是古人讲“南橘北枳”的道理。面对互联网,保险需要“知己知彼”,需要“因地制宜”,更要清晰并坚守自我。*重要的是不能照搬照抄,更不能盲目跟风,赶时髦,要有所取舍,扬长避短,为我所用,定义并打造互联网保险的技术和商业模式。

  在互联网保险的发展过程中,往往容易陷入互联网行业的“集体亢奋”状态。“亢奋”不是一件坏事,做事业,尤其是做一番前无古人的大事业,热情和激情均是必不可少的。但保险是一种平滑机制,不能太“跌宕起伏”,更不能“心惊肉跳”。因此,“淡定”很重要。保险需要日积月累,不能太“急功近利”,更懂得“敬畏时间”。因此,“定力”很重要。同时,要记得:能够成就大事业的重要前提是“不忘初心”,做互联网保险,*重要的是不能忘记“我是谁”。互联网保险,“互联网”是形容词,“保险”是主语,因此,互联网保险还是保险,切莫“数典忘祖”。

  射悻合同的特征决定了保险具有一定“虚”的成分,而互联网的“虚”是不言而喻的,两个“虚”相遇,决定了互联网保险注定要面对一场虚实观的挑战。无论是保险,还是商业,信用均是基础、灵魂和命根子。要知道:虚则不实,不实则不信,因此,如何将互联网保险做“实”,无疑是一个难题,但又是无法回避的。都说只要思想不滑坡,办法总是比困难多,因此,解决思想认识问题是基础,是关键,清晰、坚定并践行正确的互联网保险虚实观是重要路径。韩非子曾经说过:存亡在虚实,不在众寡。这句话,对盲目地沉迷于“流量”的人们无疑是一副清醒剂,更是给了互联网保险虚实观以启迪。做互联网保险的人应明白:做实难,做实也不难,难的是“诚实心意”。

  互联网保险的基本属性决定了科技,尤其是科技创新能力至关重要,因此,加大投入也就势在必行。但问题的关键不是要不要投入,而是如何投入,回答如何投入的前提是回答为什么投入。当下让人有点忧心忡忡的是:不知道从什么时候开始,“烧钱”成为了一种流行,甚至是时髦。在老百姓看来,钱,是不能拿来“烧”的,太可惜了,也犯法。钱,是用来花的,花钱过日子。“烧钱”,那是“烧”给死人的。咋一听,有点“风马牛不相及”,仔细想想,个中道理,似乎也相通。

  科技创新的本质是提**率,创造价值。风险投资的本意是为了通过一种制度安排,有效分散风险,激励创新探索,为社会创造价值。但任何事情均有个度,“度”的这边是鼓励探索,“度”的那边是纵容盲目,甚至“居心叵测”。因此,要高度关注社会层面的科技创新总绩效问题,科学和理性应当成为社会创新文化的重要内涵。

  创新和创业都不容易。正是不易,更要心存敬畏,不能任性。不是有句话说:出来混,都是要还的。创业者更要有一份清醒,有的时候,你烧的不仅是投资者的钱,还有自己的大好时光和机会。

  流量是互联网经济的起点,也是关键,所以有了那句话:流量为王。因此,所有的竞争均围绕引流展开,与此同时,也孕育了独特的商业模式。从互联网保险发展的情况看,引流成本,或业务获取成本畸高是一个不争的现实,又是一种“无能为力”的无奈。

  从表面看,这种高额“买路钱”的背后,是行业缺乏自身的销售能力,缺乏自己的渠道,因此,不得不仰仗于人,受制于人。同时,行业内部的恶性竞争,相互厮杀,也是导致这种结果的重要原因和推手。但从根本看,在当今互联网社会,保险公司,尤其是中小保险公司是难以与那些大型的互联网门户抗衡的。因此,需要从社会公平的角度看问题。中国的商业伦理讲的是:君子爱财,取之有道。而互联网门户,依仗自身的市场势力,漫天要价,强取豪夺,严重侵害了社会公共利益,要知道,这种高额的“买路钱”*终还是要由消费者和社会买单的,显然,这种“商业模式”与“道”是渐行渐远,乃至背道而驰,应当引起全社会的高度关注。值得注意的是这种互联网“商业模式”已经导致了线上成本甚至高于线下成本的问题,这无疑是饮鸩止渴,乃至是自掘坟墓。

  在中国,做保险本不容易,在互联网上做保险就更不容易。但正是因为“不容易”,就要更加珍惜,更加诚信。近来,有些“网红”的健康保险产品,采用了“全免”的承保政策,引发“爆款”效应。但问题的关键是“宽进”能否“宽出”?如果一开始就预谋着“宽进严出”,那么,诚信何在,天理何在。古人说:己所不欲勿施于人,况且谁都不傻,如果非要这么做,终究要付出更大的代价。此外,一些“大手笔”的优惠措施,是否有科学,特别是数据依据,能否守约,能否持久,也值得质疑。一时吸引眼球固然刺激,但日子还需要慢慢过,保险更是这样。也许有人说,亏钱没关系,反正烧的是VC的钱,但VC的钱总有烧完的一天,重要的是“没有了钱烧”的日子怎么过。更让人担忧的是,一阵风过后,VC还是昨天的VC,你已不是从前的你。

  互联网保险是需要发展,但更需要理性发展;业务需要增长,但必须是有益增长,而不是有害增长。任何时代,总有些人比较任性,但这种“任性”的后果往往是要社会和行业买单的,因此,发展互联网保险,作为个体,切莫“不管不顾”,作为行业,对少数人的“不管不顾”,不能视而不见,听之任之。

  纵观人类社会发展的历史,所有的进化,包括了技术、制度和社会,乃至大千世界,均遵循着遗传、突变和选择的规律,互联网保险也不可能例外。发展互联网保险,首先,是把握根本,即回答并坚守保险的根本,解决好“传承”问题。其次,是善于创新,即实现创新发展,特别是本质创新,解决好“突变”问题。第三,是不忘初心,即要做到万变不离其宗,取舍自如,这种“选择”的本质是道法自然。

  互联网保险是个新概念,发展互联网保险更需要传统文化的滋养。中国古人说:人能弘道,非到弘人。在互联网保险的发展过程中,“主语”是人,包括企业、行业和客户,即是靠人去弘互联网的道,而不是由互联网来弘人,这个“道”就是利用互联网技术更好地为客户提供服务,为社会创造福祉,为行业谋求发展。就互联网保险而言,什么是自己的“道”,真的要好好想想,切莫辜负时代。

  要“弘道”,关键是要“厚德”,“厚德”方可“载物”。要“弘道”,更需要“行深”,“行深”才能“致远”。面向未来,中国保险业,也包括互联网保险可谓是:任重道远。走好未来的路,远见卓识,开疆拓土固然重要,但集体共识,克己复礼,厚德载物,道行天下更重要。

保险学者,中国人保财险执行副总裁

转自新浪财经

暂无评论!
我要评论 只有购买过该商品的用户才能评论。

Major Chinese biopharmaceutical company Hansoh Pharmaceutical Group Company Limited (Hanmori Pharmaceutical Group Co., Ltd., Hanso Pharmaceutical) and AI ) Atomwise, Inc., a leader in the field, announced the collaboration. The purpose of the collaboration is to design and discover potential drug candidates for a total of 11 private target proteins in multiple therapeutic areas.Atomwise and Hansoh Pharma scientific teams work closely together in each program. The combination of complementary expertise and technology has the potential to dramatically increase success rates and shorten schedules in drug discovery and clinical development.Dr. Aifeng Lyu, President of Jiangsu Hansoh Pharmaceutical Group Co., Ltd., a subsidiary of Hansoh Pharma, said: “Atomwise is the best partner for Hansoh Pharma to use AI technology to innovate and create diverse small molecule pipelines in oncology and other therapeutic areas. I am very impressed with the team and I believe that working together will provide a special opportunity to develop first-in-class and best-in-class therapeutics. "Dr. Abraham Heifets, CEO of Atomwise, said: “It is a great pleasure for us to partner with Chinese biopharmaceutical giant Hansoh Pharma. Hansoh Pharma shares our strong commitment to innovation and our mission to influence patient health globally.”Atomwise's world-class AI platform for structure-based drug design leads the way in finding hit compounds, selecting lead compounds from hit compounds, and optimizing lead compounds. Hansoh Pharma will contribute in its capacity in biological assays and medicinal chemistry, and will lead the subsequent preclinical and clinical development.Subject to the terms of the collaboration, Atomwise will receive revenue based on private technology fees, option exercise fees, royalties, and sublicenses and sales of assets created under the collaboration. Based on historical average sales of small molecule drugs, the overall potential value of this transaction for Atomwise may exceed the potential value of a hit drug if all projects succeed. Hansoh Pharma receives development and commercialization rights in all fields and regions.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

Akari Therapeutics, Plc, a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for nomacopan for the treatment of bullous pemphigoid (BP).“BP, a severe blistering skin condition with no approved treatments, is an exciting therapeutic target for our lead drug candidate, nomacopan. It is also a disease of increasing prevalence due to an aging population and improving diagnosis,” said Clive Richardson, Chief Executive Officer of Akari Therapeutics. “Orphan drug designation for nomacopan is a major step forward for the program, positioning nomacopan for eligibility for an additional seven years of marketing exclusivity in BP if nomacopan is approved by the FDA. This news is in addition to the recent orphan drug designation received for our HSCT-TMA program.”The Company plans to release new safety and efficacy data from an ongoing Phase II trial with nomacopan in patients with BP at an oral presentation by Dr. Christian Sadik at the 28th European Academy of Dermatology and Venereology (EADV) Congress on October 10, 2019. In August, the Company announced new data demonstrating the synergistic benefits of nomacopan’s dual C5 and LTB4 inhibitory activity in pemphigoid disease, generated by Dr. Christian Sadik’s group at University of Lubeck, Germany, and published in the August 2019 edition of JCI Insight [link].Orphan drug designation by the FDA is granted to promote the development of drugs that target conditions affecting 200,000 or fewer U.S. patients annually and that are expected to provide significant therapeutic advantage over existing treatments. Orphan designation qualifies Akari for various benefits, including seven years of market exclusivity following marketing approval, tax credits on U.S. clinical trials, eligibility for orphan drug grants, and a waiver of certain administrative fees.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

China's leading biopharmaceutical company Hansoh Pharmaceutical Group Company Limited (" Hansen Pharmaceutical ") and drug discovery artificial intelligence (AI) Atomwise, Inc. (" Atomwise ") , a leader in the field, announced a collaborative design and discovery of potential drug candidates for up to 11 unexposed target proteins in a variety of therapeutic areas.Atomwise and Hansen Pharmaceutical's scientific team will work closely together in these projects. The combination of complementary expertise and technology is expected to significantly increase success and reduce timelines for drug discovery and clinical development.Dr. Lu Aifeng, President of Jiangsu Hansoh Pharmaceutical Group Co., Ltd., said: Hansen Pharmaceutical is committed to using AI technology to innovate and develop diverse small molecules in the field of cancer and other therapeutics. Atomwise is the right partner for Hansen Pharmaceuticals. We are very impressed with Atomwise's AI platform, capabilities and team. We believe that the two companies will have an excellent opportunity to develop similar and best-in-class therapeutic drugs. ."Dr. Abraham Heifets, CEO of Atomwise, said: "We are very excited to work with Hansen Pharmaceutical, China's leading biopharmaceutical company. Hansen Pharmaceuticals and we all have strong commitment to innovation and a common mission to influence the health of patients worldwide. ."The world-class AI platform for Atomwise structured drug design will guide efforts in hit discovery, accidental discovery to hit-to-lead selection, and optimization of lead compounds. Hansen Pharmaceuticals is committed to biological testing and pharmaceutical chemistry, as well as leading subsequent preclinical and clinical development activities.Under the terms of the partnership, Atomwise will receive undisclosed technology royalties, optional royalties, royalties, and subcontracting authorizations or revenue generated from the sale of the derivative assets. Based on the historical average turnover of small molecule drugs, the potential total value of all successful projects with Atomwise's transaction may exceed potential selling drugs. Hanson Pharmaceuticals will receive development and commercialization rights in all fields and geographies.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

WEDNESDAY, SEPTEMBER 11, 2019I-Mab Biopharma (I-Mab), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of potential first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases announces the signing of a collaboration agreement with Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences), an innovation-driven biopharmaceutical company to evaluate the combination therapy of I-Mab's TJD5, a proprietary innovative CD73 antibody with Junshi Biosciences' Toripalimab (Trade name: Tuoyi), a recombinant humanized anti-PD-1 monoclonal antibody in patients with cancers in China.Dr. Jingwu Zang, Founder and Chairman of I-Mab, commented, "TJD5 is an innovative CD73 antibody with best-in-class potential that has entered into Phase I trial in the US. We are very pleased to collaborate with Junshi to explore the clinical synergies with Toripalimab which is an innovative drug with distinctive treatment advantages. We are looking forward to bringing more clinical benefits to patients across various cancer types."Dr. Ning Li, CEO of Junshi Biosciences, commented, "As an anti multi-tumor drug, toripalimab has shown good safety and efficacy in clinical trials with mono and combination therapy. We believe, through the cooperation with I-Mab, we could continue to explore the combination potential of toripalimab and innovative drugs to improve the outcomes of immune-oncology therapy, lightening hope for more patients.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

TUESDAY, SEPTEMBER 10, 2019ProBioGen AG, a premier service and technology provider for complex therapeutic antibodies and glycoproteins, today announced the closing of a license agreement with Bayer AG for the  GlymaxX® Technology. Under the terms of the agreement, Bayer will leverage the technology to further increase the potency of an undisclosed antibody candidate for oncological indications.ProBioGen’s proven antibody-dependent cellular cytotoxicity (ADCC) enhancing technology GlymaxX® will be applied during cell line development.“We are glad to add Bayer to our list of licensees”, says ProBioGen’s Chief Executive Officer Dr. Wieland Wolf. “The GlymaxX® technology is clinically proven and is a very flexible technology which is liked by all cell lines.”About ProBioGen AGProBioGen is a premier, Berlin-based specialist for developing and manufacturing complex therapeutic antibodies and glycoproteins. Combining both state-of-the-art development services, based on ProBioGen’s CHO.RiGHT™ expression and manufacturing platform, together with intelligent product-specific technologies yields biologics with optimized properties.Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team.All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).ProBioGen was founded 1994, is privately owned, and located in Berlin, Germany.About GlymaxX®The GlymaxX® technology, developed by ProBioGen, prevents the cellular synthesis of the sugar “fucose” and hence, in antibody-producing cells, its addition to the N-linked carbohydrate part of the antibody. The absence of fucose is known to greatly enhance ADCC. The GlymaxX® technology is based on the stable introduction of a gene for an enzyme which blocks the producer cells’ fucose biosynthesis pathway. As a unique feature, differentiating it from other approaches, GlymaxX® can be applied to both novel or already existing antibody producer cell lines, and entire antibody expression and discovery platforms, without negatively affecting their productivity or other product characteristics.Furthermore, a single GlymaxX® cell line can be flexibly used to produce differently fucosylated products, depending on the upstream process: In fucose-free medium the antibody is quantitatively afucosylated. The same GlymaxX® cell line grown in fucose-containing medium however, uses the provided fucose and produces fully fucosylated antibody. Thus, a GlymaxX® cell line can by employed to produce different products: For instance ADCC-enhanced GlymaxX® antibodies or wildtype-like, fully fucosylated mAbs, for a parallel Antibody-Drug-Conjugate (ADC) project.Finally, GlymaxX® has been used by biosimilar-developing companies to adjust a specific content of fucose in order to match the originators glycoprofile. Overall, GlymaxX® is simple, rapid, potent, and universally applicable to different CHO hosts and all other eukaryotic cell species.ProBioGen offers its GlymaxX® technology royalty-free and non-exclusively as a service or as an individual license.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

About Us
Contact Us
Zensee_Daystar online